Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Alemtuzumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cellectis Provides Financial Results for the Second Quarter 2024
    Cellectis Provides Financial Results for the Second Quarter 2024

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925531/0/en/Cellectis-Provides-Financial-Results-for-the-Second-Quarter-2024.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    FDA Grants Orphan Drug Designation To Cellectis' CLLS52 For ALL
    FDA Grants Orphan Drug Designation To Cellectis' CLLS52 For ALL

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2923264/0/en/FDA-Grants-Orphan-Drug-Designation-to-Cellectis-CLLS52-alemtuzumab-For-ALL-Treatment.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share
    Genzyme`s Lemtrada (alemtuzumab) Receives Suppl Approval in the U.S.
    Genzyme`s Lemtrada (alemtuzumab) Receives Suppl Approval in the U.S.

    20 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    20 May 2024
    Share Share
    Genzyme`s Campath (alemtuzumab) Receives Suppl Approval in the U.S.
    Genzyme`s Campath (alemtuzumab) Receives Suppl Approval in the U.S.

    20 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    20 May 2024
    Share Share
    Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.
    Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.

    08 Feb 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103948

    FDA
    08 Feb 2024
    Share Share
    Stem cell transplants may slow disability progression in MS
    Stem cell transplants may slow disability progression in MS

    22 Dec 2022

    // Caroline Peachey EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/177879/stem-cell-transplants-may-slow-disability-progression-in-ms/

    Caroline Peachey EUROPEANPHARMACEUTICALREVIEW
    22 Dec 2022
    Share Share